邁信林(688685.SH):新絲路擬減持不超166.75萬股
格隆匯6月8日丨邁信林(688685.SH)公佈,公司於近日收到新絲路出具的《關於江蘇邁信林航空科技股份有限公司股份減持計劃的吿知函》,因自身經營需要,擬減持不超166.75萬股,佔公司總股本的1.49%。通過集中競價交易方式減持的,在任意連續60日內減持公司股份的數量不超過公司股份總數的1%,減持期間自減持計劃公吿之日起15個交易日後的12個月內;通過大宗交易方式減持的,在任意連續60日內減持公司股份的數量不超過公司股份總數的2%,減持期間自減持計劃公吿之日起15個交易日後的12個月內。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.